Biotech and Pharmaceuticals Biotechnology

More

  • biopharmaceuticals

    Sarepta was down sharply a day after an FDA advisory committee voted against recommending the company's Duchenne muscular dystrophy drug.

  • Sarepta a wild stock 'not for everyone': Najarian

    Discussing the play on Sarepta Therapeutics as its Duchenne muscular dystrophy drug sees pressure from FDA, with the FMHR traders.

  • VRX vs. PRGO for CEO

    CNBC's Meg Tirrell reports on the possibility of Perrigo CEO Joseph Papa heading over to Valeant, as well as biotech firm Interxon feeling some pressure after the release of a report calling it 'the new Theranos.'

  • CAMBRIDGE, England, April 22- AstraZeneca, working with genome pioneer Craig Venter, is launching a massive gene hunt in the most comprehensive bet yet by a pharmaceutical firm on the potential of genetic variations to unlock routes to new medicines. AstraZeneca will work with Venter's U.S. company Human Longevity Inc, which will sequence the genomes, including...

  • Nasdaq CEO's outlook on bank earnings, IPOs &more

    Robert Greifeld, Nasdaq CEO, discusses bank earnings, the IPO market, and more at the eMerge Americas conference.

  • Federal regulators are investigating blood-testing start-up Theranos over whether it misled investors.

  • Adam Parker recommends biotech

    Adam Parker, Morgan Stanley chief U.S. equity strategist, thinks biotech and pharma look attractive, in discussing his market forecast.

  • Sean Parker speaking at the 2015 CGI Annual Meeting in New York.

    Following his announcement to donate $250 million for cancer research, Sean Parker joined CNBC to discuss his initiative.

  • Pro: Earnings guidance to be cautiously optimistic, 'cringe-worthy'

    David Seaburg, Cowen & Company Head of Sales & Trading, and Tobias Levkovich, Citi Chief U.S. Equity Strategist, discuss the current state of the markets going into earnings season.

  • 2016 a lull for health care: Pro

    Discussing drug pricing, product approvals in the health care industry, and what's to come from the sector, with Matt Maley, Miller Tabak managing director & equity strategist, and Ian Somaiya, BMO Capital biotech analyst.

  • Trader: I don't have enough of this sector

    Is it time to buy biotech as the sector is breaking out?

  • The FMHR traders look at retail earnings, and the health of biotech stocks right now.

  • Biometrics: Future of mobile payments?

    BehavioSec provides biometric security to customers. Its founder, Olov Renberg discusses fundraising and why banks are intrigued by BehavioSec’s product.

  • Time to bet on biotech?

    Les Funtleyder, E Squared Asset Management Portfolio Manager, and David Seaburg, Cowen & Company Managing Director and Head of Sales & Trading, discuss the biotech sector and how investors should approach it.

  • April 4- A stem cell therapy developed by Vericel Corp helped reduce deaths and hospitalizations in advanced heart failure patients, according to data from a midstage study, potentially providing a treatment that could delay the need for heart transplants. "It's a little baffling that you're keeping patients alive, but not having any effect on those secondary...

  • Can you buy biotech this low?

    FMHR trader Jim Lebenthal says biotech goes higher from here as the sector continues to fade. The FMHR traders discuss pressure from the presidential campaign on the biotech space.

  • Trading biotech, health care unknowns

    Biotechs are still sinking, so when should you buy these stocks? The FMHR traders and Stephanie Link, TIAA Equities portfolio manager, share their strategy.

  • Buying beatdown biotech? Be careful!: Pro

    Les Funtleyder, E Squared Asset Management, and CNBC's Meg Tirrell, discuss whether there is more pain to come in biotech and if the pullback presents a buying opportunity.

  • Avoid biotech until elections? Analyst's view

    The number one biotech analyst Mark Schoenebaum, Evercore ISI pharma analyst, weighs in on the selloff in the space, and which stocks have the potential to go higher this year.

  • Biotech stocks too risky?

    RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.